PL3434669T3 - Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich - Google Patents
Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednichInfo
- Publication number
- PL3434669T3 PL3434669T3 PL18188873T PL18188873T PL3434669T3 PL 3434669 T3 PL3434669 T3 PL 3434669T3 PL 18188873 T PL18188873 T PL 18188873T PL 18188873 T PL18188873 T PL 18188873T PL 3434669 T3 PL3434669 T3 PL 3434669T3
- Authority
- PL
- Poland
- Prior art keywords
- intermediate compounds
- huperzine
- synthesis
- utilizable
- compounds utilizable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449198P | 2011-03-04 | 2011-03-04 | |
| EP12755750.2A EP2681199B1 (en) | 2011-03-04 | 2012-02-17 | Process for the preparation of (-)-huperzine a |
| PCT/US2012/025628 WO2012121863A1 (en) | 2011-03-04 | 2012-02-17 | (--)- huperzine a processes and related compositions and methods of treatment |
| EP18188873.6A EP3434669B1 (en) | 2011-03-04 | 2012-02-17 | Intermediate compounds utilizable in synthesis of (-) huperzine and process for obtain one of these intermediate compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3434669T3 true PL3434669T3 (pl) | 2021-05-31 |
Family
ID=46798513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12755750T PL2681199T3 (pl) | 2011-03-04 | 2012-02-17 | Sposób wytwarzania (-)-hupercyny A |
| PL18188873T PL3434669T3 (pl) | 2011-03-04 | 2012-02-17 | Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12755750T PL2681199T3 (pl) | 2011-03-04 | 2012-02-17 | Sposób wytwarzania (-)-hupercyny A |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10059672B2 (pl) |
| EP (2) | EP3434669B1 (pl) |
| JP (2) | JP5922157B2 (pl) |
| KR (1) | KR102017123B1 (pl) |
| CN (2) | CN106117140B (pl) |
| AU (2) | AU2012226251B2 (pl) |
| CA (1) | CA2829026C (pl) |
| ES (2) | ES2701730T3 (pl) |
| MX (1) | MX346339B (pl) |
| PL (2) | PL2681199T3 (pl) |
| WO (1) | WO2012121863A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10287249B2 (en) * | 2014-10-03 | 2019-05-14 | Amphastar Pharmaceuticals, Inc. | Methods of resolving racemic mixture to obtain (−)-huperzine A |
| US20180333365A1 (en) * | 2017-05-19 | 2018-11-22 | Biscayne Neurotherapeutics, Inc. | Modified release pharmaceutical compositions of huperzine and methods of using the same |
| CN109200051A (zh) * | 2017-07-03 | 2019-01-15 | 南京和博生物医药有限公司 | 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途 |
| JP7566661B2 (ja) | 2021-02-22 | 2024-10-15 | 株式会社ニッセイ | 差動減速機 |
| CN114702391B (zh) * | 2021-12-17 | 2024-09-03 | 青岛科技大学 | 一种利用双氧水进行霍夫曼重排制环丙胺的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5104880A (en) * | 1991-05-01 | 1992-04-14 | Mayo Foundation For Medical Education And Research | Huperzine a analogs as acetylcholinesterase inhibitors |
| USRE38460E1 (en) | 1994-12-28 | 2004-03-09 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Huperzine A derivatives, their preparation and their use |
| CN1052225C (zh) * | 1994-12-28 | 2000-05-10 | 中国科学院上海药物研究所 | 石杉碱甲衍生物,其制备方法和用途 |
| JPH0995483A (ja) * | 1995-07-27 | 1997-04-08 | Sagami Chem Res Center | （１１Ｅ）−５−アミノ−１１−エチリデン−５，６，９，１０−テトラヒドロ−７−メチル−５，９−メタノシクロオクタ［ｂ］ピリジン−２（１Ｈ）−オン誘導体およびその製造中間体 |
| JPH1036352A (ja) * | 1996-07-23 | 1998-02-10 | Sagami Chem Res Center | （１１Ｅ）−５−アミノ−１１−エチリデン−５，６，９，１０−テトラヒドロ−５，９−メタノシクロオクタ［ｂ］ピリジン−２（１Ｈ）−オン誘導体およびその製造中間体 |
| AU8925998A (en) | 1997-09-03 | 1999-03-22 | Macro Hi-Tech Jv, Ltd. | Huperzine a derivatives |
| US6271397B1 (en) | 1998-06-05 | 2001-08-07 | Showa Denko Kabushiki Kaisha | L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same |
| US6271379B1 (en) * | 2000-03-08 | 2001-08-07 | Georgetown University | Intermediates useful for the synthesis of huperzine A |
| EP1300396B1 (en) | 2000-06-12 | 2009-01-14 | Eisai R&D Management Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| CA2609612C (en) * | 2005-05-23 | 2014-09-23 | President & Fellows Of Harvard College | Use of huperzine to treat epilepsy |
| CN101130520B (zh) * | 2006-08-24 | 2010-05-12 | 中国科学院上海药物研究所 | 经非对映异构体盐的外消旋体拆分制备天然(-)-石杉碱甲和非天然(+)-石杉碱甲的新方法 |
| CN100528844C (zh) * | 2007-04-20 | 2009-08-19 | 中国科学院昆明植物研究所 | 石杉碱甲衍生物,其制备方法和其应用 |
| US20090247754A1 (en) * | 2008-03-25 | 2009-10-01 | Debiopharm S.A. | Method of preparing huperzine a and derivatives thereof |
-
2012
- 2012-02-17 ES ES12755750T patent/ES2701730T3/es active Active
- 2012-02-17 WO PCT/US2012/025628 patent/WO2012121863A1/en active Application Filing
- 2012-02-17 CN CN201610463124.2A patent/CN106117140B/zh active Active
- 2012-02-17 CN CN201280020578.2A patent/CN103687849B/zh active Active
- 2012-02-17 PL PL12755750T patent/PL2681199T3/pl unknown
- 2012-02-17 KR KR1020137026077A patent/KR102017123B1/ko active IP Right Grant
- 2012-02-17 JP JP2013557736A patent/JP5922157B2/ja active Active
- 2012-02-17 US US14/003,213 patent/US10059672B2/en active Active
- 2012-02-17 PL PL18188873T patent/PL3434669T3/pl unknown
- 2012-02-17 AU AU2012226251A patent/AU2012226251B2/en active Active
- 2012-02-17 MX MX2013010025A patent/MX346339B/es active IP Right Grant
- 2012-02-17 CA CA2829026A patent/CA2829026C/en active Active
- 2012-02-17 EP EP18188873.6A patent/EP3434669B1/en active Active
- 2012-02-17 EP EP12755750.2A patent/EP2681199B1/en active Active
- 2012-02-17 ES ES18188873T patent/ES2847229T3/es active Active
-
2016
- 2016-04-13 JP JP2016080553A patent/JP6200996B2/ja active Active
-
2017
- 2017-07-11 AU AU2017204748A patent/AU2017204748B2/en active Active
- 2017-12-20 US US15/848,350 patent/US10457643B2/en active Active
-
2019
- 2019-09-16 US US16/571,720 patent/US10781179B2/en active Active
-
2020
- 2020-06-04 US US16/892,828 patent/US11142503B2/en active Active
-
2021
- 2021-09-23 US US17/482,996 patent/US20220064123A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2794907A4 (en) | METHODS AND MATERIALS FOR EVALUATING LOSS OF HETEROZYGOTIA | |
| EP2667714A4 (en) | METHOD OF PREPARING 4-AMINO-5-FLUORO-3-HALO-6- (SUBSTITUTE) PICOLINATES | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| ZA201208151B (en) | Methods for improving quality of sleep | |
| HK1199245A1 (en) | Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted) picolinates 4--3--5--6-()-2- | |
| IL223220A (en) | A process for producing the history of extinacidine and its intermediates | |
| ZA201305582B (en) | Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates | |
| IL226405A0 (en) | Methods and compounds useful in synthesis@aminodihydrothializin@fused | |
| EP2731429A4 (en) | COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE | |
| PL2640711T3 (pl) | Ulepszony sposób otrzymywania rufinamidu | |
| HK1187493A1 (en) | Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted)picolinates 4--3--5--6-()-2- | |
| SG11201406623PA (en) | Process for the preparation of rivaroxaban and intermediates thereof | |
| IL227711A0 (en) | Phenyl-isoxazole history and their preparation process | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| EP2672963A4 (en) | METHOD FOR THE TREATMENT OF MELANOMA | |
| PL3434669T3 (pl) | Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich | |
| ZA201207397B (en) | Process for the preparation of dexlansoprazole | |
| IL225915A0 (en) | 5-trifluoromethyl-4-nitro-2-isoxazoline compounds and their preparation process | |
| ZA201404277B (en) | Process for making magnolol and derivatives thereof | |
| PT2603319E (pt) | Processo para a preparação de uretanos | |
| PT2593423E (pt) | Processo para a preparação de agentes de contraste | |
| ZA201108148B (en) | Triazine-aryl-bis-indoles and process for preparation thereof | |
| EP2725357A4 (en) | IFRET PROBE AND ITS USE | |
| PL391702A1 (pl) | Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny | |
| PL391303A1 (pl) | Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny |